Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Exkivity
Pharma
Takeda takes $770M in write-downs amid Alofisel, Exkivity woes
Stem cell Alofisel recently flunked a phase 3 trial in Crohn's disease fistulas, while cancer med Exkivity is being pulled from the market worldwide.
Zoey Becker
Oct 26, 2023 12:27pm
Takeda, Kyowa Kirin, Biogen—Fierce Pharma Asia
Oct 6, 2023 8:35am
After trial flop, Takeda to pull Exkivity worldwide
Oct 3, 2023 9:55am
BMS-BeiGene, Sumitomo-Otsuka, AstraZeneca—Fierce Pharma Asia
Aug 4, 2023 8:50am
Takeda's Exkivity, a rival to J&J, fails in lung cancer trial
Jul 31, 2023 10:33am
J&J touts Rybrevant win in newly diagnosed NSCLC
Jul 17, 2023 11:10am